Meaningful end points and outcomes in men on active surveillance for early-stage prostate cancer

Current Opinion in Urology

Volumn 24, Issue 3, 2014, Pages 288-292

  Welty, Christopher J ^a   Cooperberg, Matthew R ^a   Carroll, Peter R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

active surveillance; outcomes; prostate cancer

Indexed keywords

CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER MORTALITY; CANCER RISK; CANCER SPECIFIC SURVIVAL; EARLY CANCER; HUMAN; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SURVIVAL; TREATMENT FREE SURVIVAL; WATCHFUL WAITING; BIOASSAY; CANCER STAGING; DISEASE COURSE; DISEASE FREE SURVIVAL; MALE; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME; UNNECESSARY PROCEDURE;

DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; HUMANS; MALE; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNNECESSARY PROCEDURES; WATCHFUL WAITING;

EID: 84898544423     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0000000000000039     Document Type: Review

References (35)

1. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011; 364:1708- 1717.
2. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012; 367:203-213.
3. Mohler JL, Armstrong AJ, Bahnson RR. Prostate cancer, version 3. 2012 featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012; 10:1081-1087.
4. Schatzkin A, Freedman LS, Dorgan J, et al. Surrogate end points in cancer research: a critique. Cancer Epidemiol Biomarkers Prev 1996; 5:947-953.
5. Godtman RA, Holmberg E, Khatami A, et al. Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Goteborg randomised population-based prostate cancer screening trial. Eur Urol 2013; 63:101-107.
6. Klotz L. Active surveillance: the Canadian experience. Curr Opin Urol 2012; 22:222-230.
7. Selvadurai ED, Singhera M, Thomas K, et al. Medium-term outcomes of active surveillance for localised prostate cancer. Eur Urol 2013; 64:981-987.
8. Tosoian JJ, Trock BJ, Landis P, Feng Z. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011; 29:2185-2190.
9. Bul M, Zhu X, Valdagni R, et al. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol 2013; 63:597-603.
10. Cary KC, Cowan JE, Sanford M, et al. Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies. Eur Urol 2013; doi:10.1016/j.eururo.2013.08.060 [Epub ahead of print].
11. Xia J, Trock BJ, Cooperberg MR, et al. Prostate cancer mortality following active surveillance versus immediate radical prostatectomy. Clin Cancer Res 2012; 18:5471-5478.
12. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005; 293:2095- 2101.
13. Abern MR, Aronson WJ, Terris MK, et al. Delayed radical prostatectomy for intermediate-risk prostate cancer is associated with biochemical recurrence: possible implications for active surveillance from the SEARCH database. Prostate 2013; 73:409-417.
14. Dall'Era MA, Cowan JE, Simko J, et al. Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment. BJU Int 2011; 107:1232-1237.
15. Cooperberg MR, Cowan JE, Hilton JF. Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol 2011; 29:228-234.
16. Porten SP, Whitson JM, Cowan JE, et al. Changes in cancer volume in serial biopsies of men on active surveillance for early stage prostate cancer. J Urol 2011; 186:1825-1829.
17. Porten SP, Whitson JM, Cowan JE, et al. Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. JCO 2011; 29:2795- 2800.
18. van den Bergh RCN, Vasarainen H, Van Der Poel HG, et al. Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study. BJU Int 2010; 105:956-962.
19. Eggener SE, Mueller A, Berglund RK, et al. A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol 2013; 189:S19-S25.
20. Dall'Era MA, Cooperberg MR, Chan JM, et al. Active surveillance for earlystage prostate cancer: review of the current literature. Cancer 2008; 112:1650-1659.
21. Freedland SJ, Kane CJ, Amling CL, et al. SEARCH Database Study Group: Upgrading and downgrading of prostate needle biopsy specimens: risk factors and clinical implications. Urology 2007; 69:495-499.
22. McKenney JK, Simko J, Bonham M, True LD. The potential impact of reproducibility of Gleason grading in men with early stage prostate cancer managed by active surveillance: a multiinstitutional study. J Urol 2011; 186:465-469.
23. Vickers AJ, Savage C, O'Brien MF. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol V 186 2009; 27:398-403.
24. Ross AE, Loeb S, Landis P, Partin AW. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 2010; 28:2810-2816.
25. Whitson JM, Porten SP, Hilton JF, et al. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. J Urol 2011; 185:1656-1660.
26. Litwin MS, Lubeck DP, Spitalny GM, Henning JM. Mental health in men treated for early stage prostate carcinoma. Cancer 2002; 95:54-60.
27. Johansson E, Steineck G, Holmberg L, Johansson JE. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. Lancet OncolV 12 2011; 891- 899.
28. Vasarainen H, Lokman U, Ruutu M, Taari K. Prostate cancer active surveillance and health-related quality of life: results of the Finnish arm of the prospective trial. BJU Int 2012; 109:1614-1619.
29. Bellardita L, Rancati T, Alvisi MF, et al. Predictors of health-related quality of life and adjustment to prostate cancer during active surveillance. Eur Urol 2013; 64:30-36.
30. Bergman J, Litwin MS. Quality of life in men undergoing active surveillance for localized prostate cancer. J Natl Cancer Inst Monogr 2012; 2012:242-249.
31. Cooperberg MR, Carroll PR, Klotz L. Active surveillance for prostate cancer: progress and promise. JCO 2011; 29:3669-3676.
32. Newcomb LF, Brooks JD, Carroll PR, et al. Canary prostate active surveillance study: design of a multiinstitutional active surveillance cohort and biorepository. Urology 2010; 75:407-413.
33. Lin DW, Lin DW, Newcomb LF, et al. Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res 2013; 19:2442-2450.
34. Cooperberg MR, Simko JP, Cowan JE, et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. JCO 2013; 31:1428-1434.
35. Knezevic D, Goddard AD, Natraj N, et al. Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genomics 2013; 14:690.